Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1155/2015/348798 http://scihub22266oqcxt.onion/10.1155/2015/348798 C4452336!4452336 !26090489     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26090489 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26090489 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       J+Immunol+Res 2015 ; 2015 (ä): 348798 Nephropedia Template TP {{tp|p=26090489 |t=2015. The Novel PKC? from Benchtop to Clinic |pdf=|usr=}}{{26090489 }} gab.com Text The Novel PKC from Benchtop to Clinic JO: J Immunol Res http://www.kidney.de/pget.php?&tw=1&pmid=26090489 #FOAvip The protein kinases C (PKCs) are a family of serine/threonine kinases involved in regulating multiple essential cellular processes such as survival, proliferation, and differentiation. Of particular interest is the novel, calcium-independent PKC? which plays a central role in immune responses. PKC? shares structural similarities with other PKC family members, mainly consisting of an N-terminal regulatory domain and a C-terminal catalytic domain tethered by a hinge region. This isozyme, however, is unique in that it translocates to the immunological synapse between a T cell and an antigen-presenting cell (APC) upon T cell receptor-peptide MHC recognition. Thereafter, PKC? interacts physically and functionally with downstream effectors to mediate T cell activation and differentiation, subsequently leading to inflammation. PKC?-specific perturbations have been identified in several diseases, most notably autoimmune disorders, and hence the modulation of its activity presents an attractive therapeutic intervention. To that end, many inhibitors of PKCs and PKC? have been developed and tested in preclinical and clinical studies. And although selectivity remains a challenge, results are promising for the future development of effective PKC? inhibitors that would greatly advance the treatment of several T-cell mediated diseases. Twit Text FOAVip The Novel PKC from Benchtop to Clinic ????J Immunol Res http://www.kidney.de/pget.php?&tw=1&pmid=26090489 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26090489 #FOAvip English Wikipedia <ref>{{Cite pmid|26090489 }}</ref> The Novel PKC? from Benchtop to Clinic #MMPMID26090489 Hage-Sleiman R ; Hamze AB ; Reslan L ; Kobeissy H ; Dbaibo G J Immunol Res 2015[]; 2015 (ä): 348798 PMID26090489 show ga The protein kinases C (PKCs) are a family of serine/threonine kinases involved in regulating multiple essential cellular processes such as survival, proliferation, and differentiation. Of particular interest is the novel, calcium-independent PKC? which plays a central role in immune responses. PKC? shares structural similarities with other PKC family members, mainly consisting of an N-terminal regulatory domain and a C-terminal catalytic domain tethered by a hinge region. This isozyme, however, is unique in that it translocates to the immunological synapse between a T cell and an antigen-presenting cell (APC) upon T cell receptor-peptide MHC recognition. Thereafter, PKC? interacts physically and functionally with downstream effectors to mediate T cell activation and differentiation, subsequently leading to inflammation. PKC?-specific perturbations have been identified in several diseases, most notably autoimmune disorders, and hence the modulation of its activity presents an attractive therapeutic intervention. To that end, many inhibitors of PKCs and PKC? have been developed and tested in preclinical and clinical studies. And although selectivity remains a challenge, results are promising for the future development of effective PKC? inhibitors that would greatly advance the treatment of several T-cell mediated diseases. |Animals [MESH] |Antigen-Presenting Cells/immunology/metabolism [MESH] |Autoimmune Diseases/immunology/metabolism [MESH] |Humans [MESH] |Inflammation/immunology/metabolism [MESH] |Isoenzymes/immunology/metabolism [MESH] |Protein Kinase C/*immunology/*metabolism [MESH] |Receptors, Antigen, T-Cell/immunology/metabolism [MESH]The Novel PKC? from Benchtop to Clinic (epmc).pdf DeepDyve Pubget Overpricing